Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Says Hepsera Will Benefit From New Competition In Hep B Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Chronic hepatitis B market will be expanded by competitors' disease-awareness campaigns, Gilead says. Bristol-Myers Squibb's Baraclude cleared FDA in March; Roche's Pegasys user fee deadline is in May.

You may also be interested in...



Bristol-Myers Squibb’s Hepatitis B Therapy Baraclude Will Be Available April 8

Entecavir clears FDA after a six-month priority review. Baraclude labeling includes data showing superior efficacy versus GlaxoSmithKline’s Epivir-HBV. Bristol will detail the product to the 3,500 physicians who treat most U.S. cases of hepatitis B using a Baraclude-specific sales force.

Roche Pegasys sBLA Filing For Hepatitis B Could Receive Priority Review

Roche announced simultaneous U.S. and European submissions July 21; six-month review would set user fee date at mid-January. Roche is likely to highlight superiority to GlaxoSmithKline’s Epivir-HBV and efficacy in HBeAg-negative patients in promotions.

Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial

The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel